Your browser doesn't support javascript.
loading
The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma.
Nargund, Amrita M; Pham, Can G; Dong, Yiyu; Wang, Patricia I; Osmangeyoglu, Hatice U; Xie, Yuchen; Aras, Omer; Han, Song; Oyama, Toshinao; Takeda, Shugaku; Ray, Chelsea E; Dong, Zhenghong; Berge, Mathieu; Hakimi, A Ari; Monette, Sebastien; Lekaye, Carl L; Koutcher, Jason A; Leslie, Christina S; Creighton, Chad J; Weinhold, Nils; Lee, William; Tickoo, Satish K; Wang, Zhong; Cheng, Emily H; Hsieh, James J.
Affiliation
  • Nargund AM; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Pham CG; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Dong Y; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Wang PI; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Osmangeyoglu HU; Department of Computational Biology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Xie Y; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Aras O; Gerstner Sloan Kettering School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Han S; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Oyama T; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Takeda S; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Ray CE; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Dong Z; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Berge M; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Hakimi AA; Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Monette S; Laboratory of Comparative Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Lekaye CL; Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Koutcher JA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Leslie CS; Department of Computational Biology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Creighton CJ; Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA.
  • Weinhold N; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Lee W; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Tickoo SK; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Wang Z; Department of Cardiac Surgery, Cardiovascular Research Center, University of Michigan, Ann Arbor, MI 48109, USA.
  • Cheng EH; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: chenge1@mskcc.org.
  • Hsieh JJ; Molecular Oncology, Department of Medicine, Siteman Cancer Center, Washington University, St. Louis, MO 63110, USA. Electronic address: jhsieh@wustl.edu.
Cell Rep ; 18(12): 2893-2906, 2017 03 21.
Article in En | MEDLINE | ID: mdl-28329682
ABSTRACT
PBRM1 is the second most commonly mutated gene after VHL in clear cell renal cell carcinoma (ccRCC). However, the biological consequences of PBRM1 mutations for kidney tumorigenesis are unknown. Here, we find that kidney-specific deletion of Vhl and Pbrm1, but not either gene alone, results in bilateral, multifocal, transplantable clear cell kidney cancers. PBRM1 loss amplified the transcriptional outputs of HIF1 and STAT3 incurred by Vhl deficiency. Analysis of mouse and human ccRCC revealed convergence on mTOR activation, representing the third driver event after genetic inactivation of VHL and PBRM1. Our study reports a physiological preclinical ccRCC mouse model that recapitulates somatic mutations in human ccRCC and provides mechanistic and therapeutic insights into PBRM1 mutated subtypes of human ccRCC.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Transcription Factors / Nuclear Proteins / Carcinoma, Renal Cell / HMGB Proteins / Von Hippel-Lindau Tumor Suppressor Protein / Kidney Neoplasms Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Cell Rep Year: 2017 Type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Transcription Factors / Nuclear Proteins / Carcinoma, Renal Cell / HMGB Proteins / Von Hippel-Lindau Tumor Suppressor Protein / Kidney Neoplasms Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Cell Rep Year: 2017 Type: Article Affiliation country: United States